Analysis of complex cutaneous reactions using animal models allows for the identification of essential or modulatory participants, that is, cyto-and chemokines or adhesion molecules. However, complex whole animal modeling is bound to obscure some specific contributions of individual players. Mouse models suggest that expression of Fas ligand (FasL) by donor T cells is essential for the cutaneous acute graft-versus-host reaction (aGvHR), a major complication after allogeneic hematopoietic stem cell transplantation. The role of FasL/Fas in human cutaneous GvHR is not known. To understand the mechanisms of cytotoxicity and inflammation in human cutaneous GvHR, we developed an organotypic model using reconstructed human epidermis (RHE) that was exposed to FasL, gamma-interferon (IFNg), or both. The model recapitulated key histological hallmarks of cutaneous aGvHR, including interface dermatitis, appearance of cytoid bodies, hypergranulosis, and expression of ICAM-1. Cytoid body formation and expression of ICAM-1 were attributable entirely to IFNg, whereas hypergranulosis was triggered by FasL. Both FasL and IFNg triggered vacuolar degeneration of keratinocytes. The validity of the RHE model of GvHR was demonstrated by histological correlation with biopsied skin from patients with acute graft-versus-host disease. FasL and IFNg each elicited potent and specific proinflammatory genomic responses in RHE. Inhibition of caspase activity dramatically augmented the FasL-induced proinflammatory responses, suggesting an ''apoptosis-versus-inflammation'' antagonism in cutaneous aGvHR and other lichenoid dermatoses.
INTRODUCTION
The lichenoid and interface dermatoses comprise a group of approximately 30 etiologically diverse inflammatory skin diseases, exemplified by lichen planus, erythema multiforme, toxic epidermal necrolysis/Stevens-Johnson syndrome, lupus erythematosus, and acute graft-versus-host disease (aGvHD). 1 Histologically, the term ''lichenoid'' refers to the presence of a band-like lymphohistiocytic infiltrate in the upper dermis, hugging and often obscuring the epidermal-dermal interface. 1 Lichen planus is the prototypical lichenoid dermatose. Interface dermatitis refers to the presence of basal cell vacuolization (hydropic degeneration), often accompanied by single cell keratinocyte apoptosis. 1 Most lichenoid infiltrates are accompanied by interface change; however, many dermatoses characterized primarily by interface change such as lupus erythematosus and poikiloderma do not show a lichenoid infiltrate. 1 Allogeneic hematopoietic stem cell transplantation is used to treat hematological malignancies and nonmalignant disorders of the blood, such as sickle-cell anemia and aplastic anemia. 2 Mature CD4 + and CD8 + T cells contained within the graft (donor bone marrow or peripheral blood stem cells) promote hematopoietic engraftment, reconstitute T-cell immunity, and mediate the beneficial graft-versus-leukemia effect. Unfortunately, both of these donor T-cell subsets also cause GvHD, the broad attack against host tissues by donor T cells. 2 GvHD is the major barrier to successful allogeneic hematopoietic stem cell transplantation; most patients who develop the severe manifestations of GvHD succumb to it or to complications of its treatment. 3 aGvHD occurs within the first 100 days after transplantation and affects the skin, liver, and gastrointestinal tract. [2] [3] [4] [5] aGvHD proceeds in 3 phases. [2] [3] [4] [5] [6] The first involves damage to host tissues by inflammation from the preparative regimen of chemotherapy and/or radiotherapy. In the second phase, recipient and donor antigen-presenting cells, as well as inflammatory cytokines, trigger the activation of donorderived T cells, which expand and differentiate into effector cells. In the third (effector) phase, activated donor T cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions (see below), perforin-granzyme B, and tumor necrosis factor a. Activated T cells in patients with aGvHD produce large amounts of gamma-interferon (IFNg). 7, 8 IFNg is involved in several aspects of aGvHD pathophysiology by (1) upregulating adhesion molecules, chemokines, and major histocompatibility (MHC) class II antigens, thus facilitating antigen presentation and effector T-cell recruitment; (2) mediating the development of pathologic processes in the gastrointestinal tract and skin during GvHD; (3) upregulating Fas expression in target tissues; (4) cooperating with bacterial LPS to trigger the production of proinflammatory cytokines and NO from macrophages; and (5) regulating the death of activated donor T cells by enhancing Fas-mediated apoptosis, thus regulating GVHD. 9 Cutaneous aGvHD presents initially an erythematous macular rash, usually on the palms, soles, and face. In a few days, the rash becomes deeper in color and spreads to trunk and limbs. It may progress to erythroderma and is usually followed by desquamation. 10 Histologically, 1,10 advanced aGvHD lesions display basal vacuolation (hydropic or liquefactive degeneration), shrunken apoptotic keratinocytes, and eosinophilic amorphous keratinocyte remnants (known as cytoid bodies or bodies of Civatte). The apoptotic keratinocytes are often accompanied by ''satellite'' lymphocytes, and this lymphocyte-associated apoptosis is known as ''satellite cell necrosis.'' Presence of hypergranulosis and the absence of a thickened epidermal basement membrane help in making the differential diagnosis of aGvHD versus several other conditions such as lupus erythematosus and dermatomyositis. The most fulminant lesions of aGvHD show numerous necrotic keratinocytes with frequent subepidermal clefting. This histology resembles erythema multiforme/toxic epidermal necrolysis. However, in erythema multiforme, the cornified and granular layers are usually normal, rather than ortho-and/or parakeratotic as is seen in aGvHD. 10 The pathophysiology of cutaneous aGvHD has been investigated in murine models. The roles of the 2 major T-cell cytolytic mechanisms, the Fas/FasL pathway (see below) and the perforin/granzyme pathway, in aGvHD have been investigated with gene-deficient T cells in models of lethal irradiation and bone marrow rescue. In MHC antigen-matched and multiple minor histocompatibility antigen-mismatched transplants, T cells from FasL-deficient mice (gld mice) induced lethal aGvHD; however, cutaneous and hepatic aGvHD were absent. 11 Braun et al 12 reported a significantly delayed mortality in the recipients of FasL-defective T cells in a MHC-mismatched spleen cell transfer model. Hattori et al 13 confirmed the role of Fas/FasL in cutaneous aGvHD using FasL-blocking antibodies. All these studies identified the Fas/FasL system as essential for the skin damage in aGvHD, at least in mouse models of the disease. Perforin-deficient T cells induced aGvHD with delayed kinetics, but histological features of cutaneous and hepatic GvHD were similar to those in recipients of wild-type T cells. 11 Although the involvement of immunocytes, such as T cells and antigen-presenting cells, in the pathophysiology of aGvHD has been extensively researched (refs. [2] [3] [4] [5] [6] 14 and references therein), the roles of targeted epithelia within the affected organs (skin, gut, and liver) are still not well understood. The concept of the ''vicious cycle'' of aGvHD, that is, that the damage to target tissues caused by activated T cells activates more T cells, causing more tissue damage, which activates more T cells, and so on, has been appreciated in the literature. 3, 4 What is lacking, however, is a detailed mechanistic understanding of the complex interplay between apoptosis and inflammatory responses in host epithelial target cell that drives the vicious cycle. Our recent work has demonstrated that FasL elicits a potent proinflammatory response in keratinocytes grown in reconstructed human epidermis (RHE). 15, 16 This response involves the production of a specific set of cytokines and chemokines, many of which have been implicated in aGvHD. The spectrum of FasLinduced inflammatory genes is modulated by IFNg. Inhibition of caspase activity dramatically augments the FasL-induced proinflammatory response of keratinocytes, demonstrating for the first time a potential ''apoptosis-versus-inflammation'' antagonism in cutaneous aGvHD. We aim to understand how host keratinocytes propagate the vicious inflammatory cycle in cutaneous aGvHD by elucidating the mechanisms that control ''apoptosis-versus-inflammation'' decision making in the lesional epidermis. Understanding these mechanisms could facilitate the development of keratinocyte-targeted strategies to prevent and treat aGvHD with reduced need for systemic immunosuppressants. This, in turn, will allow for better graftversus-tumor effects and reduce immunosuppression-related infections and cancer relapses.
Currently, GvHD can be studied using either patientderived material (tissue biopsies or blood) or animal models (murine or nonhuman primate). A human organotypic model that reproduces faithfully various aspects of cutaneous GvHR in situ will help the elucidation of the specific roles of individual cytokines implicated in the pathogenesis of cutaneous aGvHD (such as FasL and IFNg, as demonstrated below). An epidermotypic model of acute graft-versus-host reaction (aGvHR) will also facilitate the understanding of the specific roles and responses of keratinocytes in aGvHD, in the absence of interference from other epidermal cell types (eg, melanocytes and LCs). Finally, a human organotypic model of aGvHR would also be useful to test the relevance of human patients to mouse model-generated hypotheses. This is important in view of the fact that, sometimes, mouse genes do not play the same roles as the corresponding human orthologs. For instance, genetic ablation of the mouse tyrosine kinase 2 (Tyk2), a member of the Jak family of kinases, revealed the nonessential role of Tyk2 for the murine innate and acquired immunity. 17, 18 However, a homozygous Tyk2null mutation in a human patient was associated with severe hyperimmunoglobulin E syndrome, including atopic dermatitis, and inability to mount efficient defenses against viral, fungal, and mycobacterial infections, 19 suggesting a rather essential role of Tyk2 in human immunity.
MATERIALS AND METHODS

Patient Material and Antibodies
Cutaneous biopsies from 6 aGvHD cases and 3 normal controls (all anonymous to the authors and after obtaining written informed consent) were obtained from the Department of Dermatology of Oregon Health & Science University. All cases of aGvHD were diagnosed by Dr. Clifton R. White Jr, MD, director of dermatopathology at Oregon Health & Science University. Five-micrometer-thick paraffin sections were processed for immunohistochemical analysis following standard procedures. Antigen retrieval, unless specified otherwise below for specific antibodies, was performed by microwave heating in 10-mM Na-citrate buffer, pH 6.0. The following primary antibodies were used: anti-active caspase-3 (#9961; Cell Signaling Technology, antigen retrieval, pressure cooking in Na-citrate buffer), anti-FasL (N-20, #sc-834; Santa Cruz Biotechnology), anti-T-bet (#sc-21749; Santa Cruz Biotechnology), anti-ICAM1 (#sc-107; Santa Cruz Biotechnology), anti-Filaggrin (15C10; Novocastra, antigen retrieval in 1-mM EDTA, pH 8.0), anti-CD4 (Novocastra, antigen retrieval in 1-mM EDTA, pH 8.0), anti-CD8 (Novocastra, antigen retrieval in 1-mM EDTA, pH 8.0 and pressure cooking), and anti-CCR7 (MAB197; R&D Systems).
Reconstructed Human Epidermis
Primary human epidermal keratinocytes (neonatal) were propagated as described. 20, 21 For RHE, we employed the method of Poumay et al, 22 with modifications as described. 15, 16 RHEs display normal epidermal morphology including a pronounced stratum corneum and proper spatial distribution of epidermal marker proteins, such as keratin 5, keratin 1, and filaggrin (FLG) 15, 16 (Fig. 1E ). RHEs were fixed in freshly made 4% p-formaldehyde, embedded in paraffin, and after sectioning, processed for immunohistochemistry following the specific protocols recommended by the respective manufacturers for each antibody.
Chemicals and Biologicals
All commonly used chemicals were from Sigma Chemical Company. The pan-caspase inhibitor zVADfmk was from Calbiochem (San Diego, CA). Fc:FasL has been described previously. 15, 23 IFNg was from R&D Systems.
RNA Isolation and Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction
These techniques were performed as previously described. 15, 16 
RESULTS AND DISCUSSION
Interface Dermatitis, Lichenoid Tissue Reaction, and Expression of FasL and IFNg in Cutaneous aGvHD
All cutaneous aGvHD biopsies (n = 6) displayed ID manifested by basal vacuolation with shrunken apoptotic keratinocytes, cytoid bodies, and pronounced hypergranulosis, a differential diagnostic hallmark of aGvHD 10 (Figs. 2D-F) . In the areas of interface dermatitis, activation of caspase-3 was detectable by immunohistochemistry ( Figs. 2I, J) . The areas of hypergranulosis expressed strong FLG, a major protein component of the keratohyalin granules 24 (Figs. 2W, X) . Consistent with the mouse models demonstrating the essential role of FasL in the skin manifestations of aGvHD, [11] [12] [13] all human aGvHD (but not control) biopsies demonstrated infiltration with FasL + leukocytes, both in the dermis and at the dermalepidermal junction, often in areas of vacuolar keratinocyte degeneration (Figs. 2M, N) . To detect IFNg expression in situ, we performed immunohistochemical detection of the transcription factor T-bet. T-bet is required for IFNg expression and Th1 lineage commitment, both in the mouse and the human models, and is a surrogate marker for IFNg expression. [25] [26] [27] T-bet was expressed in numerous infiltrating leukocytes in aGvHD but not in control biopsies (Fig. 2P ). The leukocytic inflammatory infiltrate consisted predominantly of CD4 + or CD8 + T lymphocytes localized either in the dermis or at the dermalepidermal junction, especially in the areas of vacuolar keratinocyte degeneration (data not shown). Consistent with the inflammatory state of aGvHD, we observed expression of ICAM-1 in the aGvHD epidermis and on the endothelium of dermal blood vessels (Fig. 2S, T) but not in the control biopsies.
Reproduction of the Histopathology of Cutaneous aGvHR in an Epidermotypic Model
In an attempt to develop epidermotypic model consistent with cutaneous aGvHR, we exposed RHEs to FasL (32 ng/mL), IFNg (50 ng/mL), or both agent and assessed the morphological changes 24 hours later. RHEs displayed interface dermatitis-like reaction, manifested by vacuolar keratinocyte degeneration (Fig. 1D, asterisk (Figs. 1N, P) were induced exclusively by IFNg (either with or without FasL) but not by FasL alone. In contrast, hypergranulosis, detected by FLG expression, was triggered by FasL (either with or without IFNg) but not by IFNg alone (Figs. 1G, H) .
Thus, we have developed an epidermotypic model of cutaneous aGvHR using RHE treated with FasL, IFNg, or both. Individual hallmarks of cutaneous aGvHD morphology could be attributed to the actions of FasL (apoptosis and hypergranulosis), IFNg (apoptosis, bodies of Civatte, and expression of ICAM-1), or both (vacuolar degeneration). To the best of our knowledge, the first suggestion that cytoid bodies (also known as colloid bodies/bodies of Civatte) are remnants of apoptotic keratinocytes was made in 1979 by Weedon et al 28 in their seminal publication ''Apoptosis. Its nature and implications for dermatopathology.'' The results presented here (Figs. 1B, J) , however, argue that cytoid bodies represent a specific morphologic subtype of keratinocyte apoptosis induced by IFNg. In contrast, keratinocyte apoptosis triggered by FasL (Figs. 1C, K) is not consistent with cytoid body morphology. Consistent with such conclusion is also our failure to detect cytoid body morphology in RHEs undergoing massive keratinocyte apoptosis in response to UV radiation, tumor necrosis factor a, interleukin (IL)-1b, or combinations thereof (data not shown).
FasL-and IFNg-Specific Patterns of Gene and Protein Expression in the Epidermotypic Model of Interface Dermatitis
We investigated the effects of FasL and IFNg, either singly or together, on the expression of 16 inflammatory genes in human epidermal keratinocytes (neonatal)-derived RHE (15 cytokines and chemokines and 1 adhesion molecule, ICAM-1). To determine the effects of suppressed apoptosis on the genomic responses to FasL and IFNg, the treatments were also done in the presence or in the absence of the caspase inhibitor zVADfmk. The secretion of the corresponding cytokines and chemokines was also determined by a Luminex-100 System Version IS (Luminex, Inc) and a Human Cytokine/Chemokine LINCOplex Kit (LINCO Research, Inc). The results of these analyses are exemplified by CXCL8/IL-8, CXCL10/IP-10, and CXCL14/BRACK in Fig. 3 , whereas all the quantitative real-time reverse transcriptase polymerase chain reaction data are summarized as a ''log-scale heat map'' in Figure 4 . The pattern of gene expression derived from our RHE model (Fig. 4) overlapped significantly with the pattern of gene expression in a murine model of cutaneous aGvHD. 29 Specifically, the following genes were common between our model and the study of Sugerman et al 29 : CCL2, CCL5, CCL19, CXCL1, CXCL10, IL-1b, and ICAM-1. The importance of these findings is underscored by implications in human aGvHD. For instance, CXCL10 expression has been detected in the basal keratinocyte layer of patients with aGvHD, together with skin-homing donor T cells expressing CXCR3, the receptor for CXCL10. 30 Furthermore, all (n = 6) our patients with cutaneous aGvHD contained dermis infiltrating cells expressing CCR7, the receptor for CCL19, identified both in our RHE model ( Fig. 4 ) and by Sugerman et al 29 (data not shown). Although Sugerman et al 29 did not identify CCL20 in their mouse model, we did so in RHE (Fig.  4) . Recently, Varona et al 31 reported that in a mouse model, mortality and morbidity due to aGvHD were drastically reduced and delayed when naive T cells were derived from donor mice deficient in CCR6, the receptor for CCL20. In summary, we have developed a predictive organotypic model of cutaneous aGvHD. Interestingly, our model identified 2 novel candidate genes that have not been previously implicated in GvHD. One is thymic stromal lymphopoietin (TSLP), the most strongly induced gene by FasL 16 (Fig. 4) . The other is CXCL14/BRACK, a uniquely regulated chemokine whose constitutive expression in ''healthy'' RHE was strongly suppressed by FasL and IFNg (Figs. 3, 4 ). Our previous analysis of FasL-repressed genes in RHE identified CXCL14 as the gene most susceptible to negative regulation by FasL and the only member of the chemokine family to be suppressed in response to FasL 16 (Figs. 3, 4) . Interestingly, CXCL14 messenger RNA expression was also downregulated by IFNg (Figs. 3, 4 ). CXCL14 is constitutively expressed by basal keratinocytes in normal human epidermis, and its expression is dramatically reduced in basal and squamous cell carcinomas. 32, 33 The biological role of CXCL14 is poorly understood, due in part to the fact that the receptor for CXCL14 has not been identified to date. It has been proposed that this chemokine mediates the epidermal constitutive recruitment of CXCL14-responsive CD14 + dendritic cell (DC) precursors, thereby promoting their in situ differentiation into functional DCs and Langerhans cells. 34 Indeed, loss of CXCL14 in tumor tissue was associated with low infiltration by DCs, whereas restoration of human CXCL14 expression in tumor cells caused attraction of DC both in vitro and in vivo. 35 Interestingly, in lesional skin of patients with atopic dermatitis or psoriasis, the epidermal expression of CXCL14 messenger RNA was dramatically reduced in areas adjacent to abundant dermal T-cell infiltration. 33 We therefore hypothesize that CXCL14 may play a role as a repulsive (repellent) chemokine for skin-homing T cells and that downregulation of CXCL14 expression by inflammatory cytokines may be a necessary prerequisite for T cell-keratinocyte interactions in aGvHD. 
